Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Europe Nucleic Acid Testing/NAT Market for 100 Assays: France, Germany, Italy, Spain, UK - ResearchAndMarkets.com

DUBLIN

The "Europe Nucleic Acid Testing/NAT Market for 100 Assays: France, Germany, Italy, Spain, UK-Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts-Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing" report has been added to ResearchAndMarkets.com's offering.

This new 1,273-page comprehensive five-country report from the author is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.

The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.

Companies Mentioned

  • Abbott
  • Affymetrix
  • Agilent Technologies
  • Applied Gene Technologies
  • Arca Biopharma
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biokit
  • bioMerieux
  • Bio-Rad
  • Biotest
  • Cepheid
  • Decode Genetics
  • Diadexus
  • Eiken Chemical
  • Elitech Group
  • Enzo Biochem
  • Exact Sciences
  • Fujirebio
  • Grifols
  • Hologic
  • Illumina
  • LabCorp
  • Leica Biosystems
  • Li-Cor Biosciences
  • Myriad Genetics
  • Ortho-Clinical Diagnostics
  • PerkinElmer
  • Proteome Sciences
  • Qiagen
  • Roche
  • Scienion
  • Sequenom
  • Shimadzu
  • Siemens Healthineers
  • Sierra Molecular
  • Takara Bio
  • Tecan Group
  • Thermo Fisher

For more information about this report visit https://www.researchandmarkets.com/r/a1wags

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Tags:




×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.